<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00905021</url>
  </required_header>
  <id_info>
    <org_study_id>H 24786 / EXTENT</org_study_id>
    <nct_id>NCT00905021</nct_id>
  </id_info>
  <brief_title>Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer</brief_title>
  <acronym>EXTENT</acronym>
  <official_title>EXTENT: Exemestane (AROMASIN®) in Combination With Sunitinib (SUTENT®) in Hormone Receptor Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Breast Care Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor Breast Care Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to find out if the treatments used in this study are helpful to
      patients that are diagnosed with hormone receptor positive metastatic breast cancer. The
      investigators want to also look at any side effects that could happen while patients are on
      the study treatments. The investigators want to see if there are any changes that could show
      us if your cancer is responding to the study treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design is a phase II design. Eligible patients will undergo staging work up and
      start treatment. Every 28-day period (4 weeks) will count as a cycle. Medical evaluations
      will be performed every 4 weeks and staging work up will be repeated every 12 weeks.

      The primary objective of the study is to assess progression free survival (PFS) of treatment
      with exemestane and sunitinib in post¬menopausal subjects with hormone receptor positive
      (ER-positive and/or PR-positive) unresectable locally advanced or metastatic breast cancer
      subjects who have progressed on prior hormonal treatment.

      In addition we want to:

        1. Obtain assessments of overall response rate (ORR), clinical benefit rate (CBR), and
           overall survival (OS).

        2. Determine the safety and tolerability of the combination regimen.

        3. Study molecular changes in tissue biopsies, circulating tumor cells (CTCs), and
           circulating endothelial cells (CECs), and explore associations with treatment response
           and resistance.

      1. Blood samples will be drawn for enumeration and profiling of circulating tumor cells and
      circulating endothelial cells at study entry (prior to starting study medications), four
      weeks after starting study medications, twelve weeks after starting study medications and at
      disease progression. These samples will be strongly encouraged but the patients may decline
      any or all of them without impacting their eligibility or continuation on the study.

      2. If the patient participating on the study has an easily accessible breast mass or
      metastatic lesion (e.g. lymphadenopathy, skin metastasis, chest wall metastasis), a core
      needle or punch biopsy will be obtained at study entry (prior to starting study medications),
      four weeks after starting study medications, and at disease progression. These biopsies will
      be strongly encouraged but the patients may decline any or all of them without impacting
      their eligibility or continuation on the study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor withdrew support
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Disease Progression in Weeks</measure>
    <time_frame>Medical evaluation every 4 weeks;The study does not have a fixed time frame for each participant. Duration of therapy depends on individule response, evidence of disease progression and tolerance</time_frame>
    <description>Time from the first day of treatment to date of progression in weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Obtain Assessments of Overall Response Rate, Clinical Benefit Rate, and Overall Survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Safety and Tolerability</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Molecular Changes in Tissue Biopsies, Circulating Tumor Cells, and Circulating Endothelial Cells</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Exemestane plus Sutent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients enrolled on the study will receive treatment as follows:
Exemestane 25 mg by mouth every day.
Sunitinib 37.5 mg by mouth every day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Exemestane 25 mg by mouth every day.</description>
    <arm_group_label>Exemestane plus Sutent</arm_group_label>
    <other_name>Aromasin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sutent</intervention_name>
    <description>Sunitinib 37.5 mg by mouth every day.</description>
    <arm_group_label>Exemestane plus Sutent</arm_group_label>
    <other_name>(Sunitinib)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must have metastatic breast cancer or locally advanced not amenable to curative
             therapy.

          2. Measurable or evaluable disease are eligible.

          3. Tumors must be Estrogen Receptor (ER)-positive and/or Progesterone Receptor
             (PR)-positive.

          4. Human Epidermal Growth Factor Recepter 2 (HER2)-positive tumors are allowed but must
             have failed Herceptin therapy.

          5. Postmenopausal

          6. No more than 3 lines of chemotherapy

          7. No more than 3 lines of hormonal therapy

          8. Bisphosphonates may be given according to their product license

          9. Left ventricular ejection fraction within institutional normal limits

         10. Liver function and kidney function tests within the upper limit of normal. In patients
             with liver metastasis, liver function tests should be &lt; 5 times the upper limit of
             normal.

         11. Adequate blood counts

         12. Normal thyroid function tests.

         13. Patients with Central Nervous System (CNS) metastatic disease are allowed if the
             disease is stable for more than 3 months by CT or MRI.

         14. Adequate general health (Eastern Cooperative Oncology Group (ECOG) performance status
             0-2).

         15. Able to give informed consent and follow the procedures of the study.

        Exclusion Criteria:

          1. Patients previously treated with exemestane in any setting.

          2. Patients previously treated with sunitinib.

          3. Patients with cardiac dysfunction or active cardiac disease

          4. Patients with uncontrolled CNS metastasis.

          5. Poorly controlled hypertension

          6. Blood counts or liver and kidney tests that fall outside the ranges outlined in
             inclusion criteria 9-10 above.

          7. ECOG performance status 3 or 4.

          8. History of other malignancy within the last 5 years, except for carcinoma in situ of
             the cervix or basal cell carcinoma of the skin.

          9. History of a cerebrovascular accident, non-catheter related deep vein thrombosis, or
             pulmonary embolism in the last 5 years.

         10. Major surgical procedure or significant traumatic injury within 28 days prior to study
             entry.

         11. Premenopausal status.

         12. History of receiving any investigational treatment within 28 days of study medication
             initiation.

         13. Current known infection.

         14. Current severe, uncontrolled systemic disease (e.g., clinically significant
             cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; or
             bone fractures).

         15. Medical or psychiatric condition that in the opinion of the principal investigator
             impair their ability to participate in the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mothaffar Rimiawi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor College of Medicine, Lester and Sue Smith Breast Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2009</study_first_submitted>
  <study_first_submitted_qc>May 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2009</study_first_posted>
  <results_first_submitted>February 6, 2012</results_first_submitted>
  <results_first_submitted_qc>April 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 28, 2012</results_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor Breast Care Center</investigator_affiliation>
    <investigator_full_name>Mothaffar Rimawi</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Hormone Receptor Positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Exemestane Plus Sutent</title>
          <description>All patients enrolled on the study will receive treatment as follows:
Exemestane 25 mg by mouth every day.
Sunitinib 37.5 mg by mouth every day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2">2 patients were off study due to AE.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Exemestane Plus Sutent</title>
          <description>All patients enrolled on the study will receive treatment as follows:
Exemestane 25 mg by mouth every day.
Sunitinib 37.5 mg by mouth every day.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Disease Progression in Weeks</title>
        <description>Time from the first day of treatment to date of progression in weeks</description>
        <time_frame>Medical evaluation every 4 weeks;The study does not have a fixed time frame for each participant. Duration of therapy depends on individule response, evidence of disease progression and tolerance</time_frame>
        <population>2 patients developed disease progression.</population>
        <group_list>
          <group group_id="O1">
            <title>Exemestane Plus Sunitinib</title>
            <description>All patients enrolled on the study will receive treatment as follows:
Exemestane 25 mg by mouth every day.
Sunitinib 37.5 mg by mouth every day.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression in Weeks</title>
          <description>Time from the first day of treatment to date of progression in weeks</description>
          <population>2 patients developed disease progression.</population>
          <units>week</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="10.9" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Obtain Assessments of Overall Response Rate, Clinical Benefit Rate, and Overall Survival</title>
        <time_frame>5 years</time_frame>
        <population>The study was terminated early before target accrual.</population>
        <group_list>
          <group group_id="O1">
            <title>Exemestane Plus Sunitinib</title>
            <description>This is a single arm study. All patients received Exemestane 25mg per day and Sunitinib 37.5 mg per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Obtain Assessments of Overall Response Rate, Clinical Benefit Rate, and Overall Survival</title>
          <population>The study was terminated early before target accrual.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine the Safety and Tolerability</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Molecular Changes in Tissue Biopsies, Circulating Tumor Cells, and Circulating Endothelial Cells</title>
        <time_frame>5 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Medical evaluation every 4 weeks. The study does not have a fixed time frame for each participant. Duration of therapy depends on individule response, evidence of disease progression and tolerance.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Exemestane Plus Sutent</title>
          <description>All patients enrolled on the study will receive treatment as follows:
Exemestane 25 mg by mouth every day.
Sunitinib 37.5 mg by mouth every day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>platelets</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid function, low</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis/stomatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mothaffar Rimawi</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>713-798-1311</phone>
      <email>rimawi@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

